Tandem Diabetes Care, Inc. (NASDAQ:TNDM) reported better-than-expected fourth-quarter financial results on Thursday.
Tandem Diabetes Care reported quarterly losses of 1 cent per share which beat the analyst consensus estimate of losses of 8 cents per share. The company reported quarterly sales of $290.400 million which beat the analyst consensus estimate of $277.029 million.
Tandem Diabetes Care said it sees FY2026 sales of $1.065 billion to $1.085 billion, versus market estimates of $1.103 billion.
“2025 was a defining year for Tandem as we surpassed $1 billion in worldwide sales and set gross margin records, while modernizing our commercial operations, reshaping our business model, and driving innovation,” said John Sheridan, president and chief executive officer. “In 2026, we plan to build upon this momentum as we further strengthen …